161005-84-1 Usage
Uses
Used in Pharmaceutical Industry:
(S)-N,N-DIMETHYL-[3-(2-THIENYL)-3-(1-NAPHTHYLOXY)PROPYL]AMINE--PHOSPHORIC ACID (1:1) is used as a pharmaceutical agent for its potential to selectively interact with target molecules or biological systems. The chiral nature of the amine and the presence of the phosphoric acid salt may contribute to its efficacy in drug development, particularly in the design of enantioselective drugs that can exploit the stereochemistry for improved therapeutic outcomes.
Used in Chemical Research:
In the field of chemical research, (S)-N,N-DIMETHYL-[3-(2-THIENYL)-3-(1-NAPHTHYLOXY)PROPYL]AMINE--PHOSPHORIC ACID (1:1) serves as a valuable compound for studying the effects of chirality and functional groups on chemical reactivity and interactions. Its unique structure allows researchers to explore novel reaction pathways and mechanisms, potentially leading to the discovery of new chemical processes or materials.
Used in Biological Research:
Check Digit Verification of cas no
The CAS Registry Mumber 161005-84-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,1,0,0 and 5 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 161005-84:
(8*1)+(7*6)+(6*1)+(5*0)+(4*0)+(3*5)+(2*8)+(1*4)=91
91 % 10 = 1
So 161005-84-1 is a valid CAS Registry Number.
161005-84-1Relevant academic research and scientific papers
PREPARATION OF DULOXETINE AND ITS SALTS
-
Page/Page column 10, (2009/12/05)
The present patent application relates to a process for the preparation of Duloxetine and its salts comprising reacting (S) - (+)-N, N-Dimethyl-3-(2- thienyl)-3-hydroxypropanamine or a salt there of with 1-fluoronapthalene in the presence of sodium hydride and potassium 4-methyl benzoate; N- demethylation via formation of phenylcarbamate to obtain Duloxetine which may then converted in to a pharmaceutically acceptable salt.
IMPROVED PROCESS FOR THE ASYMMETRIC SYNTHESIS OF DULOXETINE
-
Page/Page column 4, (2008/06/13)
This invention provides an improved asymmetric process for the synthesis of duloxetine involving arylation of Compounds of Formula I.
Treatment of incontinence
-
, (2008/06/13)
Urinary incontinence in humans is treated by administration of venlafaxine or a compound chosen from a series of aryloxy propanamines.
Asymmetric synthesis
-
, (2008/06/13)
This invention provides a stereospecific process for the synthesis of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a key intermediate in the synthesis of duloxetine.
